AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.

Category Primary study
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2021
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Epistemonikos ID: f16c75c0faba85abdaa89b5616c395278a764310
First added on: Aug 10, 2020